TRIUMPH-1 Top-Line Results — Retatrutide vs Placebo · 2,339 Participants · 80 Weeks
What Happened Today
On May 21, 2026, Eli Lilly announced positive topline results from TRIUMPH-1 — the largest and most important trial in the retatrutide Phase 3 program. This is the pivotal general obesity trial that will anchor the New Drug Application for weight management. With 2,339 participants followed for 80 weeks, it is the most definitive retatrutide efficacy dataset published to date.
All three doses of retatrutide (4mg, 9mg, 12mg) met both the primary endpoint and all key secondary endpoints. The trial was a resounding success across the board.
Perhaps most significantly, Eli Lilly confirmed that a regulatory submission is now anticipated in 2026 — suggesting an NDA filing could come before year-end, earlier than many analysts had projected.
The Weight Loss Numbers — All Doses
| Treatment Arm | Mean Weight Loss | Mean lbs Lost | ≥30% WL achieved | BMI <30 achieved |
|---|---|---|---|---|
| Placebo | −2.2% | ~5 lbs | — | — |
| Retatrutide 4mg | −19.0% | 47.2 lbs | Not reported | Significant |
| Retatrutide 9mg | −25.9% | ~64 lbs | Not reported | Significant |
| Retatrutide 12mg | −28.3% | 70.3 lbs | 45.3% of patients | 65.3% of patients |
| Retatrutide 12mg (104-wk extension, BMI ≥35) | −30.3% | 85.0 lbs | Majority | Including class 3 obesity |
How TRIUMPH-1 Compares to All Other Weight Loss Drugs
⚠ Different trials, populations, and durations. No direct head-to-head published yet. Retatrutide TRIUMPH-1 used an 80-week duration vs 72 weeks for tirzepatide's SURMOUNT-1 — longer follow-up generally produces higher numbers.
The 4mg Dose — An Underappreciated Story
The 12mg headline number is grabbing attention, but the 4mg data may be clinically more significant for real-world prescribing. At 4mg — reached with just a single dose escalation step — participants lost an average of 47.2 lbs (19.0%) at 80 weeks. That number exceeds semaglutide's best Phase 3 result (14.9%) at a far lower dose with lower side effect burden.
Discontinuation due to adverse events at 4mg was 4.1% — lower than placebo (4.9%), which is essentially background noise. This suggests the 4mg dose may offer an exceptional tolerability-to-efficacy ratio that tirzepatide and higher-dose GLP-1 drugs don't match.
Expect physicians to use 4mg as the starting target for patients concerned about GI side effects, with escalation to 9mg or 12mg for those seeking maximum weight loss.
Secondary Endpoints — Cardiometabolic Benefits
Weight loss was not the only positive finding. All three retatrutide doses produced significant improvements in cardiometabolic risk factors compared to placebo:
Waist circumference: Average reduction of 24.1 cm at 12mg — clinically meaningful visceral fat reduction that correlates with cardiovascular risk.
Non-HDL cholesterol: Significant reduction across all doses.
Triglycerides: Significant reduction — consistent with the glucagon receptor's role in hepatic lipid metabolism.
Systolic blood pressure: Clinically meaningful reduction.
High-sensitivity CRP: Significant reduction — indicating reduced systemic inflammation.
Prediabetes reversal: 65.3% of patients achieved BMI below 30 at 12mg, including 37.5% of those with class 3 obesity (BMI ≥40) at baseline.
Safety Profile
The safety profile in TRIUMPH-1 was broadly consistent with the GLP-1 drug class. Gastrointestinal adverse events predominated, as expected:
| Adverse Event | Placebo | 4mg | 9mg | 12mg |
|---|---|---|---|---|
| Nausea | 14.8% | 28.6% | ~35% | 42.4% |
| Diarrhea | 13.5% | 25.2% | ~28% | 32.0% |
| Vomiting | 4.8% | 10.6% | ~18% | 25.3% |
| Constipation | 10.9% | 23.8% | ~25% | 26.1% |
| Discontinuation (AEs) | 4.9% | 4.1% | 6.9% | 11.3% |
What This Means for FDA Approval
TRIUMPH-1 is the trial that carries the obesity NDA. With a clean positive Phase 3 result across all doses and endpoints, Eli Lilly now has the core dataset needed for regulatory submission. The company confirmed a regulatory submission is anticipated in 2026 — a meaningful acceleration from earlier guidance that had suggested late 2026 or early 2027.
Two more major readouts are still pending in 2026 — TRIUMPH-2 (obesity + type 2 diabetes) and TRIUMPH-3 (cardiovascular outcomes). These will add to the NDA package but are unlikely to be filing prerequisites for the primary obesity indication.
Using tirzepatide's path as a template: NDA filed → FDA accepted for Priority Review → approved approximately 7 months later. If Lilly files the retatrutide NDA in Q3/Q4 2026, a 2027 approval becomes genuinely achievable — potentially earlier than most analysts had forecast.
Access While You Wait
Retatrutide remains investigational and is not FDA approved. Pending approval — now projected for 2027 — research peptide vendors provide the only non-trial access route. Our two top-recommended vendors:
The Bottom Line
TRIUMPH-1 is the result the retatrutide community has been waiting for. A 2,339-patient, 80-week, double-blind randomized trial showing 28.3% weight loss at the highest dose — with 45% of patients achieving what was previously only achievable through bariatric surgery. No plateau. Improving cardiometabolic markers across the board. And a 4mg dose that outperforms the best approved GLP-1 drug at a fraction of the top dose.
The FDA submission timeline has accelerated. The data is stronger than Phase 2 suggested it would be. And with TRIUMPH-2 and TRIUMPH-3 still to come, the full picture of retatrutide's clinical profile is not yet complete.
Retatrutide is no longer "the promising Phase 2 drug." It is a Phase 3-validated obesity therapy on the cusp of regulatory submission, with efficacy data that places it in a category of its own among pharmacological weight loss interventions.
What Comes Next
June 2026 — ADA Scientific Sessions: Eli Lilly will present the full TRIUMPH-1 dataset including detailed subgroup analyses, full safety data, and likely the first detailed cardiovascular risk data.
2026 (date TBD) — TRIUMPH-2: Obesity + type 2 diabetes. Expected to show A1C reduction on top of dramatic weight loss.
2026 (date TBD) — TRIUMPH-3: Cardiovascular outcomes. The largest trial in the program. Results here could position retatrutide as the first obesity drug with a proven cardiovascular mortality benefit.
2026 Q3/Q4 — NDA Filing: Based on today's confirmation that a regulatory submission is anticipated in 2026.
2027 — FDA Decision: If Priority Review is granted, approval is possible in 2027 — potentially as early as mid-2027.
Related Pages
- →FDA approval timeline — updated with TRIUMPH-1 data
- →Complete TRIUMPH Phase 3 program overview
- →Retatrutide vs Mounjaro — updated with TRIUMPH-1
- →TRANSCEND-T2D-1 Phase 3 diabetes results
- →Live retatrutide news feed